Pazopanib API Market is segmented By Type (Min Purity Less Than 98, Min Purity 98-99, Min Purity More Than 99), By Application (Research, Pharmaceutical), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Pazopanib API Market Overview
[200 Pages Report] The Pazopanib API Market the size was valued at US$ YY billion in 2022 and is estimated to reach US$ YY billion by 2029, growing at a high CAGR during the forecast period (2024-2031).
Pazopanib API Market - Strategic Insights
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Pazopanib is an antineoplastic agent used to treat advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy.
Market Dynamics
An increase in the incidence rate of cancer disease and the increase in advanced treatments will drive the pazopanib API Market
An increase in the incidence rate of renal cancer disease will drive the market
Renal cell cancer is also called kidney cancer or renal cell adenocarcinoma, disease in which malignant (cancer) cells are found in the lining of tubules in the kidney. RCC accounts for 2% of global cancer diagnoses and deaths, it has rapidly grown in incidence in the developed world, becoming the ninth most common cancer diagnosis in the US. RCC is the deadliest urological neoplasm and has a dismal late-stage, 5-year survival rate of 12%.
Pazopanib is an inhibitor of various tyrosine kinases, including vascular endothelial growth factor receptor and platelet-derived growth factor receptors. Pazopanib is involved in inhibiting signaling pathways, angiogenesis, and cell proliferation. It was approved by the US FDA and the European Medicines Agency at the dose of 800 mg daily. Pazopanib is effective in the treatment of metastatic RCC as reported.
An increase in the advanced treatments will drive the pazopanib API market
Pazopanib (Votrient(®)) is an orally administered multi-tyrosine kinase inhibitor approved in the EU, the US, and other countries to treat advanced renal cell carcinoma. VOTRIENT® (pazopanib) tablets are indicated to treat adults with advanced renal cell carcinoma (RCC). Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. Over the last ten years, dramatic advances in the care of patients with advanced renal cell carcinoma have occurred, including insights into this disease's molecular pathogenesis, which have now been translated into paradigm-changing therapeutic strategies. The VEGF Receptor Tyrosine Kinase Inhibitor (VEGFR TKI) family of drugs grows and includes agents such as Sorafenib, Sunitinib, Axitinib, and Pazopanib. This class is broadly defined as small molecule inhibitors of the VEGF signaling cascade that exert their mechanism via the blockade of one or more VEGFR tyrosine kinases.
Side effects will hamper the pazopanib API market
Pazopanib side effects are easily predictable in terms of their onset, duration, and severity. They are almost reversible and will go away after therapy is complete. The common side effects of pazopanib are nausea, vomiting, diarrhea (which occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss, hyperglycemia, hypoglycemia, electrolyte abnormalities (including hypocalcemia, hypomagnesemia, hypophosphatemia), laboratory anomalies (including increased AST, ALT, and protein in the urine), edema, hair loss or discoloration, change in the taste, abdominal pain, rash, fatigue and bone marrow suppression (including leucopenia, neutropenia, thrombocytopenia, and lymphopenia). Pazopanib has been associated with a low but real risk of potentially fatal liver damage.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry. To curb its growth government completes a lockdown that stopped all industrial activities, hospital visits, and management of cancer patients. It also affected the pazopanib API market as the healthcare system focussed much on COVID-19 cases.
Market Segment Analysis
Minimum purity less than 98% will dominate the segment
Generally, the purity assessment of pharmaceutical grade materials involves structural characterization and the quantification of the impurities, frequently down to the 0.1% w/w level. Unless based on a specific rationale, purity thresholds of the general format >“X%” (e.g., “at least 99% pure” or “80% minimum purity”) commonly found in the journal, pharmacopoeial, and regulatory guidelines, as well as certificates of analysis, must be considered as arbitrary values.
The research segment will dominate the pazopanib API market in the forecast period
The research publications that review and collect the most relevant and important data help professionals involved in the management of patients and keep them informed of the latest developments, so literature reviews in oncology, as in other therapeutic areas are relevant and necessary. Whereas it is also known that real-world practice is much more complex and variable than the research environment
Pazopanib is a multikinase inhibitor that targets the VEGF receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and c-Kit protein, inhibiting angiogenesis. It is used in adult patients with mRCC, both as a first-line treatment and after previous treatment with cytokines.Pazopanib hydrochloride which is an oral multi-targeted tyrosine kinase receptor inhibitor with anti-tumor activity. It inhibits vascular endothelial growth factor receptor (VEGFR)-1, -2, and-3, platelet-derived growth factor receptor (PDGFR), and ckit, resulting in inhibition of angiogenesis in tumors in which these receptors are up-regulated. Pazopanib hydrochloride is in phase II/III development for breast cancer and in phase II trials in patients with gynecological cancer,peritoneal cancer, nasopharyngeal cancer, non-small cell lung cancer, pancreatic cancer, soft tissue sarcoma, and glioma.
Geographical Analysis
North America will dominate the pazopanib API market
The strong focus of this region on its R&D, the availability of good healthcare infrastructure, increased renal cancer diseases, and timely approval of new products will increase its market in this region.
Globally, the incidence of renal cell carcinoma (RCC) widely varies from region to region, with the highest observed in the North America. In the U.S, there are approximately 76,000 new cases and almost 14,000 deaths from RCC each year. The American Cancer Society estimates that by 2021 there will be 76,080 cases (48,780 in males and 27,300 in females) of malignant tumors of the kidney and renal pelvis diagnosed, with 13,780 deaths (8790 in males and 4990 in females).
Total R&D expenditures at U.S. academic institutions reached $83.7 billion in FY 2019, an increase of almost $4.5 billion (5.7%) from FY 2018
Competitive Landscape
Major key players Tecoland, FCDA, BIOBERRY, Abcr, Dr. Reddys Laboratories, Pharmaffiliates, Jigs chemical, MuseChem, Hairuichem, Wuhan Fortuna Chemical, Shijiazhuang Dingmin Pharmaceutical Sciences, AlchemyPharm and Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Pazopanib API Market Key Companies to Watch
Dr. Reddys Laboratories
Overview: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company which is committed to provide affordable and innovative medicines for healthier lives. They have businesses of Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products. Their major therapeutic areas of focus are gastrointestinal, diabetology, oncology, pain management, cardiovascular and dermatology. Dr. Reddy operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.
Product Portfolio: The company offers a portfolio of products and services, including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations
Key Development: Dr. Reddy’s Laboratories has received the US Food and Drug Administration (FDA) approval for ELYXYB (celecoxib oral solution 25 mg/mL) to treat acute migraine with or without aura in adults.
